Marvell Technology, Inc. (MRVL)
| Previous Close | 42.28 |
| Open | 41.55 |
| Bid | 41.24 x 1000 |
| Ask | 41.26 x 900 |
| Day's Range | 41.06 - 41.80 |
| 52 Week Range | 33.75 - 76.59 |
| Volume | |
| Avg. Volume | 12,062,601 |
| Market Cap | 35.553B |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.24 (0.53%) |
| Ex-Dividend Date | Jan 05, 2023 |
| 1y Target Est | N/A |
- GlobeNewswire
Syntiant Corp. Strengthens Board of Directors with Appointment of Edward Frank
Visionary and Tech Entrepreneur Brings 35 Years of Experience to the Edge AI Chipmaker, Leading Industry Giants and Emerging Companies Syntiant Corp. Visionary and Tech Entrepreneur Edward Frank, Ph.D., Appointed to Syntiant Corp.'s Board of Directors IRVINE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Syntiant Corp., a provider of deep learning solutions for always-on edge AI applications, today announced the addition of Edward Frank, Ph.D., to its board of directors. Dr. Frank joins Syntiant’s b
- CNW Group
Marvell Expands Operations in Canada
Marvell (NASDAQ: MRVL) today announced a significant expansion of its Canadian presence in Ottawa, Toronto, and Vancouver with plans for ongoing growth. The company added over 120 new employees to the Marvell Canada team this year to support the continued growth and scale of its global operations. Canada is a market of growing strategic importance for Marvell as the company continues to advance its leadership in cloud-optimized silicon.
- Newsfile
Marvel Biosciences Initiates Formulation Development with Catalent
Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc.Catalent, one of the world's largest contract research organizations, has begun development of novel solid ...
